CD19 Redirected Autologous T Cells for Hodgkin Lymphoma

NCT02277522 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped unable to meet enrollment goal

Conditions

Hodgkin Lymphoma With no Available Curative Treatment Options Who Have a Limited Prognosis

Interventions

BIOLOGICAL: RNA anti-CD19 CAR T cells

Sponsor

University of Pennsylvania